Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yi Qi Xiao Liu Granules for Uterine Fibroids (Qi Deficiency and Blood Stasis Pattern) Phase II Trial
CTR20252125Phase 2Active
- Sponsor
- Fangsheng Rongda Pharmaceutical
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Yiqi Xiaoliu in Fibromyoma (LM), sponsored by Fangsheng Rongda Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
Yiqi Xiaoliu
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on CTR20252125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252125.